Latest On Sutro Biopharma, Inc (STRO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 15:17 EST | News | Sutro Biopharma GAAP EPS of -$0.85, revenue of $12.7M | N/A |  |
| 2023-05-03 15:49 EST | News | Sutro, Mersana jump after Immunogen data for ovarian cancer therapy | N/A | |
| 2023-04-11 19:04 EST | News | Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting | N/A | |
| 2023-03-31 10:48 EST | News | Sutro Biopharma GAAP EPS of -$2.35 beats by $0.16, revenue of $67.8M misses by $0.57M | N/A | |
| 2023-03-22 01:51 EST | News | Sutro Biopharma stock slides as transferred to Equal Weight at Wells Fargo | N/A | |
About Sutro Biopharma, Inc (STRO):
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental read more... Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
General
- Name Sutro Biopharma, Inc
- Symbol STRO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 182
- Fiscal Year EndDecember
- IPO Date2018-09-27
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.sutrobio.com
Valuation
- Trailing PE 54.26
- Price/Sales (Trailing 12 Mt.) 14.95
- Price/Book (Most Recent Quarter) 4.48
- Enterprise Value Revenue 18.27
- Enterprise Value EBITDA 41.71
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.56
- Profit Margin 28%
- Operating Margin -134%
- Return on Assets -16%
- Return on Equity 7%
- Revenue 45.75 million
- Earnings Per Share $0.44
- Revenue Per Share $1.62
- Gross Profit -22876000
- Quarterly Earnings Growth 45.2%
Highlights
- Market Capitalization 1.09 billion
- EBITDA -36933000
- PE Ratio -3.01
- Analyst Target Price $29.43
- Book Value Per Share $6.41
Share Statistics
- Shares Outstanding 45.61 million
- Shares Float 34.47 million
- % Held by Insiders 1111%
- % Held by Institutions 88.44%
- Shares Short 1.14 million
- Shares Short Prior Month 1.03 million
- Short Ratio 2.56
- Short % of Float 3%
- Short % of Shares Outstanding 3%
Technicals
- Beta 0.79
- 52 Week High $28.3
- 52 Week Low $6.91
- 50 Day Moving Average 23.26
- 200 Day Moving Average 18.4
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Sutro Biopharma, Inc (STRO) Dividend Calendar:
Sutro Biopharma, Inc (STRO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Sutro Biopharma, Inc (STRO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Sutro Biopharma, Inc (STRO) Chart:
Sutro Biopharma, Inc (STRO) News:
Below you will find a list of latest news for Sutro Biopharma, Inc (STRO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sutro Biopharma, Inc (STRO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest STRO Trades:
Sutro Biopharma, Inc (STRO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-10-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-09 | 8-K (Current report) | |
| 2020-09-04 | 8-K (Current report) | |
| 2020-08-28 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-25 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | 8-K (Current report) | |
Sutro Biopharma, Inc (STRO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sutro Biopharma, Inc (STRO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1111%
Institutional Ownership: 8844%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-05 | Trevor Hallam | Chief Scientific Officer | Sell | 16,751.00 | 15.00 | 251,265.00 | 36,712.00 | |
| 2020-11-05 | Trevor Hallam | Chief Scientific Officer | Buy | 16,751.00 | 4.36 | 73,034.36 | 53,463.00 | |
| 2020-10-05 | Trevor Hallam | Chief Scientific Officer | Buy | 9,182.00 | 4.36 | 40,033.52 | 36,712.00 | |
| 2020-09-28 | Trevor Hallam | Chief Scientific Officer | Sell | 975.00 | 10.26 | 10,006.72 | 27,530.00 | |
| 2020-09-25 | EDWARD C ALBINI | CFO and Secretary | Buy | 7,174.00 | 13,556.00 | | ||
| 2020-09-25 | Anik Shabbir | Chief Technical Ops. Officer | Buy | 8,609.00 | 14,241.00 | | ||
| 2020-09-25 | LINDA A FITZPATRICK | Chief People & Comm. Officer | Buy | 7,576.00 | 16,583.00 | | ||
| 2020-09-25 | WILLIAM J NEWELL | CEO | Buy | 25,252.00 | 191,879.00 | | ||
| 2020-09-25 | ARTURO MD MOLINA | Chief Medical Officer | Buy | 8,609.00 | 20,692.00 | | ||
| 2020-09-25 | Trevor Hallam | Chief Scientific Officer | Buy | 11,019.00 | 27,809.00 | | ||
| 2020-09-25 | Trevor Hallam | Chief Scientific Officer | Buy | 6,887.00 | 30,886.00 | | ||
| 2020-09-18 | John Gordon Freund | Director | Sell | 400,000.00 | 12.00 | 4,800,000.00 | 560,053.00 | |
| 2020-09-11 | John Gordon Freund | Director | Sell | 500,000.00 | 10.00 | 5,000,000.00 | 960,053.00 | |
| 2020-08-26 | Trevor Hallam | Chief Scientific Officer | Sell | 975.00 | 9.04 | 8,818.29 | 16,790.00 | |
| 2020-08-19 | John Gordon Freund | Director | Sell | 500,000.00 | 8.72 | 4,360,000.00 | 1,460,053.00 | |
| 2020-07-27 | Trevor Hallam | Chief Science Officer | Sell | 975.00 | 8.06 | 7,858.21 | 17,765.00 | |
| 2020-06-26 | Trevor Hallam | Chief Science Officer | Sell | 975.00 | 8.02 | 7,817.65 | 18,740.00 | |
| 2020-05-26 | Trevor Hallam | Chief Science Officer | Sell | 975.00 | 10.00 | 9,753.32 | 19,715.00 | |
| 2020-05-14 | ARTURO MD MOLINA | Chief Medical Officer | Buy | 6,451.00 | 7.75 | 49,995.25 | 12,083.00 | |
| 2020-05-14 | WILLIAM J NEWELL | CEO | Buy | 64,516.00 | 7.75 | 499,999.00 | 166,627.00 | |